Ribas, A., Mehmi, I., Medina, T., Lao, C., Kummar, S., Amin, A., … Long, G. V. (2018). Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. Ann Oncol, 29 Suppl 8, viii451–viii452. https://doi.org/10.1093/annonc/mdy289.021

Ribas, A., I. Mehmi, T. Medina, C. Lao, S. Kummar, A. Amin, S. Deva, et al. “Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy.” Ann Oncol 29 Suppl 8 (October 2018): viii451–52. https://doi.org/10.1093/annonc/mdy289.021.

Ribas A, Mehmi I, Medina T, Lao C, Kummar S, Amin A, et al. Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. Ann Oncol. 2018 Oct;29 Suppl 8:viii451–2.

Ribas, A., et al. “Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy.” Ann Oncol, vol. 29 Suppl 8, Oct. 2018, pp. viii451–52. Pubmed, doi:10.1093/annonc/mdy289.021.

Ribas A, Mehmi I, Medina T, Lao C, Kummar S, Amin A, Deva S, Salama AK, Tueting T, Milhem M, Hoimes CJ, Daniels G, Shaheen M, Jang S, Barve M, Powell A, Chandra S, Schmidt EV, Janssen R, Long GV. Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy. Ann Oncol. 2018 Oct;29 Suppl 8:viii451–viii452.